Bioequivalence of the Tablet and Liquid-Filled Capsule Forms of MK0974 (0974-042)

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1

Total Enrollment

50 participants

Study Classification

INTERVENTIONAL

Study Start Date

2008-03-31

Study Completion Date

2008-05-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study will demonstrate the definitive bioequivalence of a solid dose formulation of MK0974 to the liquid filled capsule formulation of MK0974.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Bioavailability of KBP-5074 Tablet vs Capsule Formulations

NCT03340753

Bioequivalence

COMPLETED PHASE1

Bioequivalence Study of Topiramate Tablets 25mg Under Fed Conditions

NCT00902473

Healthy

COMPLETED NA

Bioequivalence Study of Torrent Pharmaceutical Ltd.'s Topiramate Tablets Under Fed Conditions

NCT00939705

Healthy

COMPLETED PHASE1

A Study to Demonstrate Bioequivalence Between 6 x 2 mg Tablets of Perampanel and a Single 12 mg Tablet of Perampanel in Healthy Subjects

NCT01240187

Partial Onset Epilepsy

COMPLETED PHASE1

Bioequivalence Study of Torrent Pharmaceutical Ltd.'s Topiramate Tablets Under Fasted Conditions

NCT00939692

Healthy

COMPLETED PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Migraine

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

CROSSOVER

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

1

MK0974 Tablet

Group Type EXPERIMENTAL

MK0974 tablet

Intervention Type DRUG

MK0974 280 mg tablet in one of two treatment periods

2

MK0974 Liquid filled capsule

Group Type ACTIVE_COMPARATOR

Comparator: MK0974 liquid filled capsule

Intervention Type DRUG

MK0974 300 mg liquid filled capsule in one of two treatment periods

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

MK0974 tablet

MK0974 280 mg tablet in one of two treatment periods

Intervention Type DRUG

Comparator: MK0974 liquid filled capsule

MK0974 300 mg liquid filled capsule in one of two treatment periods

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Subject is in good health
* Subject is a nonsmoker
* Subject is willing to comply with the study restrictions

Exclusion Criteria

* Subject has history of stroke, chronic seizures, or any major neurological disorder
* Subject has a history of cancer
* Subject is a nursing mother
* Subject has uncontrolled high blood pressure
* Subject has or has a history of any disease or condition that might made participation in the study unsafe or confound the study results

Minimum Eligible Age

18 Years

Maximum Eligible Age

55 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes